Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Cancer × Nivolumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 241 Carcinoma, Non-Small-Cell Lung 212 Carcinoma, Renal Cell 130 Neoplasm Metastasis 92 Neoplasms 87 Squamous Cell Carcinoma of Head and Neck 78 Carcinoma, Hepatocellular 75 Colorectal Neoplasms 70 Lung Neoplasms 66 Stomach Neoplasms 53 Pancreatic Neoplasms 49 Carcinoma, Transitional Cell 41 Hodgkin Disease 40 Head and Neck Neoplasms 39 Urinary Bladder Neoplasms 36 Breast Neoplasms 36 Ovarian Neoplasms 34 Triple Negative Breast Neoplasms 31 Small Cell Lung Carcinoma 29 Sarcoma 29 Brain Neoplasms 29 Kidney Neoplasms 28 Prostatic Neoplasms 27 Glioblastoma 27 Recurrence 26 Multiple Myeloma 22 Esophageal Neoplasms 22 Skin Neoplasms 20 Lymphoma 20 Uveal Melanoma 19

Interventions

Gemcitabine 4 Cisplatin 4 Carboplatin 3 pembrolizumab 2 erdafitinib 2 durvalumab 2 vinflunine 1 tremelimumab 1 niraparib 1 enfortumab vedotin 1 cabozantinib 1 avelumab 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Radiotherapy 1 Paclitaxel 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Everolimus 1 Docetaxel 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03036098 2026-03-06

CheckMate901

Bristol-Myers Squibb

Phase 3 Active not recruiting

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡